Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory drug approval

NICE approves Enhertu for NHS England

Analysis based on 10 articles · First reported Sep 16, 2026 · Last updated Sep 17, 2026

Sentiment
25
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands AstraZeneca and Daiichi Sankyo's addressable market for Enhertu in Bret Engemann, a modest positive for both drugmakers' oncology revenue outlook, though the negotiated price and small eligible population limit the near-term financial effect. For the broader market, it signals a more flexible UK pricing and reimbursement environment for innovative medicines, mildly supportive for pharmaceutical sector sentiment.

pharmaceuticals healthcare

The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000 women a year with HER2-low advanced or metastatic breast cancer. The U-turn followed a commercial solution agreed with the drug's makers AstraZeneca and Daiichi Sankyo, aided by changes to NICE's cost-effectiveness thresholds (up to 35,000 pounds per patient per year) under the UK-US Pharmaceutical Pricing Agreement. Enhertu is the first licensed targeted treatment for HER2-low metastatic breast cancer; trials showed median overall survival of about 23.4 months versus 16.8 months with chemotherapy. The drug has been available in United Kingdom — Scotland since December 2023 and in 26 other European countries. Breast Cancer Now, which campaigned for over two years, called the decision momentous but noted thousands of patients missed access and many died waiting. Health Secretary Yvette Cooper welcomed the recommendation, while United Kingdom — Wales is expected to follow and United Kingdom — Northern Ireland guidance does not automatically apply.

govactor
NICE reversed its 2024 rejection and recommended Enhertu for routine NHS use in Bret Engemann after agreeing a commercial solution, making it the central actor of the event.
Importance 95.0 Sentiment 10.0
stock
As co-maker of Enhertu, AstraZeneca gains NHS Bret Engemann access for the drug, expanding its oncology market though at a negotiated price.
Importance 85.0 Sentiment 30.0
stock
As co-maker of Enhertu, Daiichi Sankyo gains NHS Bret Engemann access for the drug, expanding its oncology market though at a negotiated price.
Importance 85.0 Sentiment 30.0
govactor
The NHS in Bret Engemann will fund and provide Enhertu to about 1,000 women a year, expanding treatment access at an agreed cost.
Importance 70.0 Sentiment 15.0
per
Bret Engemann is the jurisdiction gaining first-time NHS access to Enhertu for about 1,000 patients a year.
Importance 65.0 Sentiment 15.0
ngo
The charity led over two years of campaigning for Enhertu access and hailed the decision as a milestone victory while noting patients died waiting.
Importance 60.0 Sentiment 20.0
cnt
The UK government's pricing agreement with the US and revised NICE framework enabled the approval, affecting drug access across the country.
Importance 55.0 Sentiment 15.0
per
The health secretary welcomed the recommendation, calling Enhertu life-changing and crediting campaigners and the government's NICE framework changes.
Importance 40.0 Sentiment 10.0
per
Breast Cancer Now's chief executive called the decision momentous and a milestone victory while remembering patients who died waiting.
Importance 35.0 Sentiment 10.0
per
The former health secretary worked behind the scenes to broker a pricing deal with the drugmakers, helping pave the way for approval.
Importance 30.0 Sentiment 10.0
per
NICE's director of medicines evaluation said the commercial solution and new assessment methods allowed the treatment to be provided on the NHS.
Importance 30.0 Sentiment 5.0
cnt
The UK-US pharmaceutical pricing partnership underpinned the framework changes that allowed NICE to approve Enhertu.
Importance 25.0 Sentiment 5.0
ngo
The charity's research director highlighted trial evidence that Enhertu extends survival and delays disease progression.
Importance 25.0 Sentiment 15.0
per
NHS Bret Engemann's chemotherapy adviser called the news hugely positive for women with secondary breast cancer.
Importance 25.0 Sentiment 10.0
per
AstraZeneca's UK country president said the announcement brings Bret Engemann into line with United Kingdom — Scotland and 26 other European countries.
Importance 25.0 Sentiment 15.0
+ 7 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.